Literature DB >> 31564323

Phakic intraocular lens implantation for the correction of hyperopia.

Abdulaziz A Alshamrani1, Saad S Alharbi2.   

Abstract

The prevalence of myopia is much higher than hyperopia. Hence, there are relatively few studies investigating phakic intraocular lens (pIOL) implantation for the correction of hyperopia. This review aimed to summarize the available relevant literature on the efficacy and safety of pIOL implantation for the correction of hyperopia and hyperopic astigmatism. At present, two types of pIOLs are used to correct hyperopia and hyperopic astigmatism: anterior chamber iris-fixated pIOLs and posterior chamber implantable collamer lenses. Both have been found to be safe and effective. No serious events (eg, retinal or choroidal detachment, endophthalmitis) were reported in the reviewed articles. Implantation of pIOLs might be the optimal refractive surgery for the correction of high hyperopia.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Year:  2019        PMID: 31564323     DOI: 10.1016/j.jcrs.2019.05.051

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  4 in total

1.  Five-year clinical outcomes of rigid iris-fixated phakic intraocular lens in northern Chinese.

Authors:  Jun Li; Lin-Lin Song; Hui Song
Journal:  Int Ophthalmol       Date:  2022-04-05       Impact factor: 2.029

Review 2.  In vivo optical quality of posterior-chamber phakic implantable collamer lenses with a central port.

Authors:  Robert Montés-Micó; Francisco Pastor-Pascual; Enrique Artiaga-Elordi; Ramón Ruiz-Mesa; Pedro Tañá-Rivero
Journal:  Eye Vis (Lond)       Date:  2021-08-16

3.  Phaco with ICL in situ in a case of high hyperopia.

Authors:  Sri Ganesh; Supriya Samak Sriganesh; Sushmitha Samak Sriganesh; Skanda Samak Sriganesh
Journal:  Am J Ophthalmol Case Rep       Date:  2022-01-26

4.  Long-term follow-up for monovision surgery by Implantable Collamer Lens V4c implantation for myopia correction in early presbyopia.

Authors:  Yuhao Ye; Jing Zhao; Zhe Zhang; Lingling Niu; Wanru Shi; Xiaoying Wang; Xingtao Zhou
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-02-07       Impact factor: 3.535

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.